1. ALLA AKTIER
  2. NYHETER
  3. SYNACT PHARMA

SynAct Pharma

Nyheter SynAct Pharma Nyheter alla bolag

Change in number of shares and votes in SynAct Pharma AB

LHFI

SynAct Pharma AB (the "Company") announces that the number of shares and votes has increased by 2,521,451 as a result of the preferential share issue, including the payment in shares to the guarantors, resolved upon by the extraordinary general meeting on 13 December 2024.

Today, the last trading day of the month, the total number of shares and votes in the Company amounts to 49,008,918.

For further information, please contact:
Jeppe Øvlesen, CEO SynAct Pharma
Tel: +45 2844 7567
Email: JOO@synactpharma.com 

About SynAct Pharma AB
SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and anti-inflammatory activity in autoimmune and inflammatory diseases to help patients achieve immune balance and overcome their inflammation. For more information: www.synactpharma.com.

This information is information that SynAct Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-01-31 18:00 CET.

Attachments
Change in number of shares and votes in SynAct Pharma AB

Datum 2025-01-31, kl 18:00
Källa MFN
Bifogade filer
Change in number of shares and votes in SynAct Pharma AB
Affiliate
SAVR är investeringsplattformen som utmanar branschen och gör det både enklare och roligare att investera. Betala aldrig för mycket! Alla aktier och ETF:er från 1 kr, och få upp till 50 % rabatt på alla fonder. Automatiskt courtage och samma enkla prismodell på alla marknader.
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet